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Abnormal architecture of the tumor blood network, as well as heterogeneous erythrocyte flow, leads to temporal
fluctuations in tissue oxygen tension exposing tumor and stromal cells to cycling hypoxia. Inflammation is another
feature of tumormicroenvironment and is considered as a newenabling characteristic of tumor progression. As cycling
hypoxia is known to participate in tumor aggressiveness, the purpose of this study was to evaluate its role in tumor-
promoting inflammation. Firstly, we assessed the impact of cycling hypoxia in vitro on endothelial inflammatory
response induced by tumor necrosis factor α. Results showed that endothelial cells exposed to cycling hypoxia
displayed an amplified proinflammatory phenotype, characterized by an increased expression of inflammatory
cytokines, namely, interleukin (IL)-6 and IL-8; by an increased expression of adhesion molecules, in particular
intercellular adhesion molecule–1 (ICAM-1); and consequently by an increase in THP-1 monocyte adhesion. This
exacerbation of endothelial inflammatory phenotype occurs through nuclear factor–κB overactivation. Secondly, the
role of cycling hypoxia was studied on overall tumor inflammation in vivo in tumor-bearing mice. Results showed that
cycling hypoxia led to an enhanced inflammation in tumors as prostaglandin-endoperoxide synthase 2 (PTGS2), IL-6,
CXCL1 (C-X-C motif ligand 1), and macrophage inflammatory protein 2 (murine IL-8 functional homologs) mRNA
expression was increased and as a higher leukocyte infiltration was evidenced. Furthermore, cycling hypoxia–specific
inflammatory phenotype, characterized by a simultaneous (baculoviral inhibitor of apoptosis repeat-containing 5)low/
PTGS2high/ICAM-1high/IL-6high/IL-8high expression, is associatedwith a poor prognosis in humancoloncancer. This new
phenotype could thus be used in clinic tomore precisely define prognosis for colon cancer patients. In conclusion, our
findings evidenced for the first time the involvement of cycling hypoxia in tumor-promoting inflammation amplification.
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During tumor uncontrolled development, some tumor cells become
too distant from blood vessels and receive an insufficient oxygen
supply. These cells are thus in condition of hypoxia, defined as a
reduced level of oxygen. This type of hypoxia, called chronic hypoxia,
results from the limited diffusion of oxygen from blood capillaries
through the tumor [1]. During the avascular phase, tumor cells
proliferate, but the proliferation is counterbalanced by cell death,
maintaining tumor mass in a dormancy state. To grow, tumor
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via hypoxia-inducible factor-1 (HIF-1) and/or from genetic instability
[2,3]. Thanks to the angiogenic switch, tumor develops its own blood
network. However, this network is structurally abnormal and
dysfunctional [4,5]. Tumor vessels are tortuous and leaky, with an
inconstant diameter, arteriovenous shunts, excessive branching, and
blind ends, and they lack a conventional hierarchy [4]. Blood flow is
highly irregular and sluggish and could be temporally obstructed by
circulating blood cells or be restricted because of mechanical
compression of microvessels by proliferating tumor cells [5,6]. The
resulting irregular flow leads to cycling hypoxia, also termed acute or
intermittent [7]. Cycling hypoxia is characterized by a pattern of
periodicity between hypoxia and reoxygenation periods. Dewhirst
identified two overlapping time scales for temporal fluctuations in
tumor pO2, which are fluctuations over days occurring from
angiogenesis and vasculature remodeling and fluctuations over
hours (one to three cycles per hour) resulting from fluctuations in
erythrocyte flow because of the chaotic architecture of tumor blood
network [6]. Interestingly, cycling hypoxia may affect more cell types
than chronic hypoxia, in particular endothelial cells, one of the
numerous cell types presents in the “tumor ecosystem.” Even if cancer
has long been defined as a disease involving transformed cells, it is
now clear that it must be considered as a disease implicating multiple
heterotypic interactions between malignant cells and stromal cells
[3,8]. The proliferation of tumor cells alone cannot lead to cancer, but
a suitable microenvironment for this proliferation promotes tumor
growth and metastasis. Furthermore, the notion of inherent
inflammation in tumor microenvironment has emerged [9]. Studies
on the immune system have highlighted innate and adaptive immune
responses supporting tumor growth instead of its rejection. Indeed,
immune system components may be hijacked by tumor cells to favor
tumor growth and metastasis. Mantovani firstly suggested that
cancer-related inflammation could emerge as the seventh hallmark of
cancer, joining the six hallmarks previously defined in 2000 [3,10].
Hanahan and Weinberg, in their new description of hallmarks of
cancer, integrated tumor-promoting inflammation as a new enabling
characteristic, contributing to the acquisition of multiple hallmark
capabilities by supplying bioactive molecules to the tumor microen-
vironment including growth or survival factors, proangiogenic factors,
and matrix-modifying enzymes [11,12]. Tumor necrosis factor
(TNF) α has been considered as a major early mediator of cancer-
related inflammation [12].
Here, the role of cycling hypoxia in tumor-related inflammation was
explored in vitro in endothelial cells and in vivo in tumor-bearing mice.
Then, cycling hypoxia–amplified inflammation was evaluated for its use
as a prognosis marker of poor outcome in human colon cancer.
Material and Methods
Cell Culture and Hypoxia Incubation
Certified EAhy926 endothelial cells (ATCC) were grown in DHG-
L1 medium (DMEM high glucose, low NaHCO3, without sodium
pyruvate) (Gibco) containing 10% fetal bovine serum (FBS). Human
umbilical vein endothelial cells (HUVEC) (pooled cells, Lonza) were
maintained in EGM (Lonza) until passage 4.
For hypoxia experiments, cells were incubated as described in [13],
with or without TNFα (R&D Systems) at 0.1 or 1 ng/ml. Normoxic
cells (N) were incubated in the same conditions but in normal
atmosphere. For chronic hypoxia (chH), cells were exposed to acontinued period of 6 hours under 1% O2. For cycling hypoxia
(cyH), cells were exposed to four consecutive cycles of 1-hour hypoxia
(1% O2) followed by 30-minute reoxygenation (air).
Mouse Model
C57BL6 mice (Elevage Janvier, Le Genest-St-Isle) received an i.m.
injection of 106 Lewis lung carcinoma (LLc) tumor cells (ATCC) in
the posterior left leg. When the tumor diameter reached 10 ±0.5 mm,
mice were randomly assigned to a treatment group (three mice per
group). Tumor-bearing mice were exposed either to normal air
(control) or to cyH, or were injected i.p. with LPS (#L6386, Sigma)
(1 mg/kg) for 44h30 hours (LPS group). Procedure of cyH was
performed as in [14]. The local authorities approved each procedure
according to animal care regulations.
Human Samples
Healthy and tumor tissues from seven patients suffering from colon
cancer (Biobank, CHU Dinant Godinne, UCL) were used for RNA
extraction to compare relative mRNA abundance by reverse
transcription quantitative polymerase chain reaction (RT-qPCR).
The study was approved by the local ethics committee (no. 73/2012).
RT-qPCR
Total RNA was extracted from cells using the QIAcube system
with RNeasy Mini kit (QIAGEN). For murine and human tissues,
RNA extraction was performed using TRIZOL reagent (Invitrogen).
RT-qPCR was performed as in [13]. RPL13A was used as the
housekeeping gene.
Immunofluorescence Staining
EAhy926 cells were seeded at 100,000 cells/well (24-well plate) on
glass coverslips. After incubation, immunofluorescence staining was
performed as described in [15] using anti–intercellular adhesion
molecule-1 (ICAM-1) antibody (#BBA3, R&D Systems) (1:100) and
Alexa Fluor 488–conjugated goat anti-mouse IgG antibody (Molec-
ular Probes) (1:1000). Observations were performed with a constant
photomultiplier gain value and a constant laser power using a confocal
microscope SP5 (Leica). Tumors were cryosliced, probed with a
monoclonal antibody against CD11b (#550282, BD Pharmingen)
(1:50), and revealed with Alexa Fluor 488 anti-rat IgG (1:300) [14].
Observations were performed using a Zeiss Axioskop microscope
equipped for fluorescence.
ELISA
Secreted interleukin (IL)-6 and IL-8 concentrations were assayed
using specific ELISA kits (Quantikine, R&D Systems) according to
supplier’s recommendations. For EAhy926 cells, concentrations were
normalized by total protein (μg proteins/ml) determined by the Folin
method.
Western Blot Analysis
Total protein extraction for ICAM-1 was performed using 10 mM
Tris pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.5% SDS, 0.1 mM
β-mercaptoethanol, Protease Inhibitor Cocktail (Roche), and Phos-
phatase Inhibitor Buffer 25× (25 mMNa3VO4, 250 mM PNPP, 250
mM β-glycerophosphate, 125 mM NaF). Nuclear protein extraction
was performed as described in [16]. Total protein extraction for
phosphorylated (Ser536) p65 was performed using 25 mM Tris pH
7.4, 150 mMNaCl, 1 mM EDTA, 1%NP-40, 5% glycerol, Protease
Inhibitor Cocktail, and Phosphatase Inhibitor Buffer 25×. Protein
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a low–fluorescence background PVDF blotting membrane
(Millipore). Quantitative LI-COR technology was used for Western
blot analyses (Odyssey Infrared Imaging System v3.0.16, LI-COR,
Biosciences). Procedure is described in [13], and antibodies used are
listed in Supplementary Table S1. Full-length blots are available in
Supplementary Figure S5.Plasmid Transfection and Luciferase Reporter Assay
EAhy926 cells (100,000 cells/well of 24-well plate) were
transiently co-transfected with 0.225 μg of pNF-κB-Firefly luciferase
reporter plasmid (Stratagene) and 0.025 μg of pRenilla luciferase-TK
using 0.5 μl of Lipofectamine 2000 (Invitrogen), following
manufacturer’s instructions. Twenty-four hours posttransfection,
cells were incubated for 6 hours under N, chH, or cyH with or
without TNFα (0.1 ng/ml and 1 ng/ml). Four hours later, cells were
lysed, and luciferase activities were measured using Dual Luciferase
Reporter Assay Kit (Promega). Firefly luciferase activity was
normalized to Renilla luciferase activity.
siRNA Transfection
EAhy926 cells were seeded at 250,000 cells/well (six-well plate).
After 24 hours, medium was replaced by 2 ml DHG-L1 medium
containing 20 nM human HIF-1α siRNA (mixture of 4 siRNA,
#M-00401805, Dharmacon) or human RelA siRNA (mixture of 4
siRNA, #L-003533-00, Dharmacon) or Non-Targeting siRNA (#D-
001810-10, Dharmacon) and INTERFERin (Polyplus Transfection)
diluted 1:250. After 24 hours, 2 ml DHG-L1 medium containing
10% FBS were added to the transfection mix. Twenty-four hours
after medium change, cells were trypsinized and seeded at 2,000,000
cells/T25. Seventy-two hours after transfection, cells were used for the
appropriate experiments.
Monocyte Adhesion on HUVEC
HUVEC were seeded at 150,000 cells/well in 24-well plates coated
with 0.2 % PBS-gelatin (#G9391, Sigma). Forty-eight hours after
seeding, cells were incubated as previously described for 6 hours.
Incubation medium was supplemented by 4 mM L-glutamine and
0.5% BSA (#A8806, Sigma). Thereafter, medium was replaced by
1 ml medium containing 600,000 calcein-labeled THP-1 monocytes,
and cells were incubated for 1 hour at 37°C. After incubation, wells
were rinsed three times with PBS. One milliliter of PBS was added,
and the fluorescence associated to the adherent leukocytes was
determined (485 nm/520 nm, Fluoroskan Ascent).
Kaplan-Meier Curves
An Affymetrix dataset containing gene expression data from 177
colon cancer patients, for whom complete demographic, histologic
grade, stage, and differentiation information are available, was used
for survival studies (downloaded from GEO, GSE17536). Procedures
of RNA extraction and hybridization are described in [17]. It has to
be noted that one patient (GSM437119) was excluded from analyses
because he died a very long time after the diagnostic. Raw data in CEL
files are publicly available and were processed according to the
method defined by Pierre et al., by using alternative CDFs from
AffyProbeMiner and GCRMA for normalization and summarization
of downloaded data in the R statistical environment [18]. Kaplan-
Meier curves were drawn with GraphPad Prism using disease-specific
survival (DSS; death from cancer) time and event (0; 1) for eachsubgroup. One hundred seventy-six patients were separated into two
equal subgroups (n=88, median value) according to the expression of
one gene. These subgroups were then subdivided when combinations
of several gene expressions were studied.Statistical Analysis
Data are reported as mean ±1 SD (in vitro) or mean ±1 SEM (in vivo).
Statistical analyseswere performed using SigmaStat Software orGraphPad
Prism. Corresponding statistical tests are outlined in figure captions.Results
Numerous studies have evidenced different consequences of cycling
hypoxia versus chronic hypoxia on cancer cell as well as on endothelial
cell behavior, altering angiogenesis, tumor growth, and metastasis
[14,16,19–21]. Nevertheless, no one until now has suggested an impact
of cycling hypoxia on tumor-related inflammation.
Cycling Hypoxia-Induced Amplified Inflammatory Phenotype
in Endothelial Cells
The effects of cycling hypoxia, compared to chronic hypoxia, were
investigated in vitro on the endothelial cell inflammatory response
induced by TNFα used at physiological concentration (0.1 ng/ml)
[22]. Cycling hypoxia was mimicked by four cycles of 1-hour hypoxia
followed by 30-minute reoxygenation. This protocol was based on in
vivo measurements of oxygen fluctuations in tumor blood networks
revealing a frequency of 0.5 to 1 cycle per hour [23]. It was
demonstrated in vitro that 1-hour hypoxia causes a rapid accumu-
lation of HIF-1α, whereas 30-minute reoxygenation is sufficient to
abrogate this accumulation [14]. This protocol showed a progressive
accumulation of HIF-1α along cycles in endothelial cells [24,25] and
permitted to observe an increase in endothelial cell migration,
tubulogenesis and resistance towards proapoptotic stresses, and an
increase in tumor cell radioresistance [14,16]. Here, EAhy926
endothelial cells and HUVEC were exposed to 6 hours of N, chH, or
cyH with or without TNFα (0.1 ng/ml). Relative mRNA expression
of IL-6, IL-8, and ICAM-1 was quantified directly after the 6 hours of
incubation (6h+0hR) (Figure 1). Cycling hypoxia rapidly increased
TNFα-induced IL-8 (Figure 1A) and ICAM-1 (Figure 1B) mRNA
level in both cell types. Interestingly, the increase in ICAM-1 mRNA
expression in HUVEC by cycling hypoxia was more discernible at a
later study time point, i.e., 4-hour reoxygenation after the 6 hours of
incubation (6h+4hR) (Supplementary Figure S1A). A cycling
hypoxia–specific increase in TNFα-induced mRNA expression of
genes encoding other adhesion molecules was observed for vascular
cell adhesion molecule-1 (VCAM-1) and selectin-E (SELE) in
HUVEC (not expressed by EAhy926 cells) (Supplementary Figure
S1, B–C). Intriguingly, this low TNFα concentration did not
increase relative IL-6 mRNA abundance (Figure 1C) even at an earlier
time point (tested after 3 hours) (data not shown). Vascular
endothelial growth factor A (VEGFA) mRNA expression was used
as positive control for chronic hypoxia (Supplementary Figure S1D).
For cycling hypoxia, we used PTGS2 mRNA expression (gene
encoding cyclooxygenase-2, COX-2) as positive control. Daneau
et al., described PTGS2 gene expression as part of cycling hypoxia gene
signature [26]. Here, cycling hypoxia increased prostaglandin-
endoperoxide synthase 2 (PTGS2) mRNA expression only in the
presence of TNFα (Supplementary Figure S1E) in HUVEC (PTGS2
is not expressed in EAhy926 cells).
Figure 1. Endothelial cells exposed to cycling hypoxia display a proinflammatory phenotype that is characterized by IL-8 and ICAM-1mRNA
overexpression. EAhy926 cells and HUVEC were exposed to N, chH, or cyH with or without TNFα (0.1 ng/ml) for 6 hours. The relative
abundance of IL-8 (A), ICAM-1 (B), and IL-6 (C)mRNAwas evaluated directly after the incubation (6h+0hR) byRT-qPCR (n=3,mean±1SD).
Statistical analysis was performed by two-way ANOVA and Holm-Sidak test as post hoc test. * chH/cyH versus corresponding N, $ cyH
versus corresponding chH, # TNFα versus corresponding control. *, $, #, P b .05; **, $$, ##, P b .01; ***, $$$, ###, P b .001.
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media harvested either directly after the incubation (6h+0hR) or after
16-hour reoxygenation (6h+16hR) to measure cytokine accumula-
tion. For IL-8, results showed the same trend as the one observed for
gene expression, that is, a highly significant increase in TNFα-
induced IL-8 secretion when endothelial cells were exposed to cycling
hypoxia (Figure 2A). Surprisingly, IL-6 secretion was also increased
by TNFα, which did not correspond to gene expression profile.
Indeed, TNFα seemed to be needed for IL-6 secretion, as the basal
level of secretion was very low. TNFα-induced IL-6 secretion was
higher under cycling hypoxia than under normoxia or chronic
hypoxia in EAhy926 cells and HUVEC (Figure 2B). Polotsky et al.,
have reported a similar discrepancy between unchanged IL-6 mRNA
abundance profile and an increase in IL-6 secretion, and they
suggested a posttranscriptional regulation occurring during protein
synthesis or secretion process [27]. A potential role of reactive oxygen
species in IL-6 secretion has been described [28]. In parallel, it was
demonstrated that TNFα stimulates reactive oxygen species
generation in EAhy926 cells [29]. Hence, both observations couldexplain the increase in IL-6 secretion under TNFα stimulation
independently of an increase in mRNA level.
ICAM-1 protein expression was firstly evaluated by immunofluores-
cence staining in EAhy926 cells (Figure 2C). Neither cycling hypoxia nor
chronic hypoxia influenced TNFα-induced ICAM-1 expression directly
after the incubation (6h+0hR). However, after 4-hour (6h+4hR) and
16-hour (6h+16hR) reoxygenation, cycling hypoxia sustained TNFα-
induced ICAM-1 expression, whereas it was strongly decreased under
normoxia or chronic hypoxia. Cycling hypoxia could increase the stability
or maintain ICAM-1 expression for a longer time. The higher abundance
of ICAM-1 protein after 16-hour reoxygenation was confirmed in
EAhy926 cells (Figure 2D) and HUVEC (Figure 2E) stimulated with
TNFα and exposed to cycling hypoxia by Western blot analyses.
Role of NF-κB in the Amplification of Inflammation Induced
by Cycling Hypoxia
The genes studied here are targets of NF-κB, the master
transcription factor that regulates inflammation. We thus investigated
whether NF-κB could be overactivated in response to cycling
Figure 2. Cycling hypoxia increases IL-6 and IL-8 secretion induced by TNFα and stabilizes TNFα-induced ICAM-1 expression along reoxygenation time. (A–E) EAhy926 cells and
HUVECwere exposed to N, chH, or cyH with or without TNFα (0.1 ng/ml) for 6 hours. (A–B) Conditioned media were recovered directly after the incubation (6h+0hR) or after 16-hour
reoxygenation (6h+16hR) and assayed to determine IL-8 and IL-6 concentration by ELISA (n=3, mean ±1 SD). Statistical analysis was performed by two-way ANOVA and Holm-
Sidak test as post hoc test. * chH/cyH versus corresponding N, $ cyH versus corresponding chH, # TNFα versus corresponding control. *, $, #, P b .05; **, $$, ##, P b .01; ***, $$$,
###, P b .001. (C) EAhy926 cells were fixed directly after the incubation (6h+0hR) or after 4-hour (6h+4hR) or 16-hour (6h+16hR) reoxygenation andwere immunostained for ICAM-
1 (green). Nuclei were labeled with TOPRO-3 (blue). (D–E) After 16-hour reoxygenation, total abundance of ICAM-1 in EAhy926 cells (D) and HUVEC (E) was detected by Western
















Figure 3. Cycling hypoxia increases the nuclear abundance of p65, the abundance of p65 phosphorylated on serine 536, and the
transcriptional activity of NF-κB, induced by TNFα. (A–B) EAhy926 cells were exposed to N, chH, or cyH with or without TNFα (0.1 ng/ml or
1 ng/ml) for 6 hours. (A) Representative immunoblots and the relative quantification bar graph represent p65 nuclear abundance
normalized by NUP98 (n=3, mean ±1 SD). (B) Representative immunoblots and the relative quantification bar graph represent the total
abundance of p65 phosphorylated on serine 536 normalized for α-tubulin (n=3, mean ±1 SD). (C) EAhy926 cells were transiently co-
transfected with the pNFκB-Fluc reporter plasmid encoding firefly luciferase and the pRL-TK normalization plasmid encoding renilla
luciferase. Twenty-four hours posttransfection, cells were exposed to N, chH, or cyH with or without TNFα (0.1 ng/ml or 1 ng/ml) for 6
hours. Luciferase activities were measured 4 hours after the incubation using dual luciferase reporter assay. Results are expressed as
mean of the ratio between firefly and renilla luciferase activity ±1 SD (n=3). (A–C) Statistical analysis was performed by two-way ANOVA
and Holm-Sidak test as post hoc test. * chH/cyH versus corresponding N, $ cyH versus corresponding chH, # TNFα versus corresponding
control, Δ TNFα 1 ng/ml versus corresponding TNFα 0.1 ng/ml. *, $, #, Δ, P b .05; **, $$, ##, ΔΔ, P b .01; ***, $$$, ###, ΔΔΔ, P b .001.
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translocation and its phosphorylation on serine 536. Results showed
that cycling hypoxia, and to a lower extent chronic hypoxia, in the
presence of TNFα increased the nuclear localization of p65
(Figure 3A) as well as the abundance of Ser536 phosphorylated p65
(Figure 3B). Finally, NF-κB transcriptional activity was studied using
a luciferase reporter assay. Results showed that cycling hypoxia led to
a significant increase in TNFα-induced NF-κB transcriptional
activity (Figure 3C). As previously described [16], cycling hypoxia
alone was not able to affect NF-κB activation in endothelial cells.
The mechanism behind the overactivation of TNFα-stimulated
NF-κB by cycling hypoxia was then investigated. In unstimulated
cells, inhibitor of NF-κB (IκB) family inhibitors sequester nuclear
factor of kappa light chain enhancer of activated B cells (NF-κB)dimers in the cytoplasm, avoiding transcription of NF-κB target
genes. Under NF-κB–activating stresses, IκB kinase (IKK) is activated
by the phosphorylation of catalytic subunits, IKKα and IKKβ.
Activated IKK then phosphorylates IκBα, leading to IκBα
ubiquitination and degradation by the proteasome, enabling active
NF-κB to translocate to the nucleus and to activate transcription. As
NF-κB pathway is known to be rapidly activated [30], we followed
the abundance of phospho-IKKα/β, phospho-IκBα, and total IκBα
proteins at each step, i.e., hypoxia or reoxygenation, for the 6 hours of
incubation under cycling hypoxia or normoxia (Figure 4A). To
facilitate the understanding of the mechanistic behind this over-
activation, experiments were performed with 1 ng/ml TNFα because
a more marked effect of cycling hypoxia could be observed on p65
nuclear localization and phosphorylation abundance (Figure 3, A–B)
Figure 4. Cycling hypoxia prolongs TNFα-induced NF-κB activation by increasing IKKα/β phosphorylation state, IκBα phosphorylation, and
thus its degradation and by slowing down the neosynthesis of IκBα. EAhy926 cellswere exposed toNor cyHwith orwithout TNFα (1 ng/ml)
for 6 hours. Experimentalmodel is depicted in (A). Phosphorylation of IκBα and IKKα/β and total abundance of IκBα and IKKαwere assessed
by Western blotting after each step of hypoxia (H1-H2-H3-H4) and reoxygenation (R1-R2-R3-R4) in comparison to N, without (B) or with
TNFα (C) (n=1). α-Tubulin was used as loading control. Bars represent phospho-IκBα fluorescence intensity normalized for total IκBα (left),
total IκBα fluorescence intensity normalized for α-tubulin (center) and phospho-IKKα fluorescence intensity normalized for IKKα (right) in
the presence of TNFα.
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lation of IκBα was observed, and the total amount of IκBα did not
vary under cycling hypoxia. However, when endothelial cells were
stimulated with TNFα, important changes in NF-κB pathway were
observed under cycling hypoxia (Figure 4C). After the first hour of
TNFα stimulation (H1), IκBα was phosphorylated and total IκBα
was almost undetectable, suggesting IκBα proteasomal degradation.
This massive degradation occurred to the same extent undernormoxia and cycling hypoxia. But at this step, a higher amount of
phosphorylated IKK under cycling hypoxia was already highlighted,
reflecting a higher IKK activity. Later on, after 1 hour and 30 minutes
of incubation (R1), a high amount of total IκBα was detected under
normoxia but not under cycling hypoxia. This phenomenon was
observed until R2 step (3 hours of incubation). In parallel, the
amount of phosphorylated IKK stayed higher under cycling hypoxia
until R2 step as well. After R2 step, no more difference between
Figure 5. NF-κB is involved in the increase in TNFα-induced IL-6 and IL-8 secretion when cells are exposed to cycling hypoxia and in the
increase in TNFα-induced ICAM-1 mRNA expression. EAhy926 cells transfected or not (Ctl) with nontargeting siRNA (siNT) or p65 siRNA
(sip65) were exposed to N, chH, or cyHwith or without TNFα (0.1 ng/ml) for 6 hours. (A) Total abundance of p65 was assessed byWestern
blotting to verify p65 silencing. α-Tubulin was used as loading control. (B–C) Directly after the incubation, conditioned media were
recovered for IL-6 or IL-8 secretion quantification by ELISA. (D) The relative abundance of ICAM-1mRNAwas evaluated by RT-qPCR. (B–D)
Results are expressed asmean±1SD (n=3). Statistical analysiswas performedby two-wayANOVAandHolm-Sidak aspost hoc test. t test
was used to compare siNT versus sip65 in the same condition. * chH/cyH versus corresponding N, $ cyH versus corresponding chH, #
TNFα versus corresponding control,× sip65 versus siNT. *, $, #, ×, P b .05; **, $$, ##, ××, P b .01; ***, $$$, ###, ×××, P b .001.
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that for longer incubation durations under normoxia, phosphorylated
IκBα rapidly decreased and IκBα seemed restored, whereas under
cycling hypoxia, the level of phosphorylated IκBα was kept higher
over time and the increase in the amount of total IκBα was slower
than in normoxia. The prolonged phosphorylation state of IκBα
could be associated with an increased phosphorylation of IKKα/β,
which is required for its activation, in cells incubated under cycling
hypoxia in comparison to normoxia. Therefore, the persistent
phosphorylation and thus degradation of IκBα as well as the slowing
down of the neosynthesis of IκBα induced by cycling hypoxia could
explain the increased NF-κB transcriptional activity.
We then examined the involvement of NF-κB in the increase in IL-8
and IL-6 secretion and in the overexpression of ICAM-1 in EAhy926
cells by knocking down p65 using siRNA (Figure 5). Silencing efficacy
was checked at the protein level by Western blot analyses (Figure 5A).
Results showed that IL-8 (Figure 5B) and IL-6 (Figure 5C) secretion
induced by TNFα and its further increase by cycling hypoxia were
completely abrogated by p65 silencing. In addition, p65 silencing
abolished the effect of cycling hypoxia in the presence of TNFα on
ICAM-1mRNA expression (Figure 5D). The involvement ofHIF-1was
also studied by knocking down HIF-1α expression, but no inhibition
of the expression of these inflammatory markers was observed
(Supplementary Figure S2). Together, these findings confirmed the
central role of NF-κB in the amplified proinflammatory phenotype of
endothelial cells in response to cycling hypoxia.Cycling Hypoxia-Induced Activated Phenotype in Endothelial
Cells
Finally, we wanted to analyze a physiological consequence of this
cycling hypoxia–amplified inflammatory phenotype. Therefore, we
evaluated monocyte adhesion to endothelial cells. Results showed that
cycling hypoxia increased THP-1 monocyte adhesion to HUVEC
stimulated by TNFα (Figure 6) and thus validated a biological
consequence of cycling hypoxia on endothelial cell function.
Cycling Hypoxia-Induced Overall Tumor Inflammation In
Vivo
To attest that cycling hypoxia could account for global tumor
inflammation in vivo, tumor-bearing mice were exposed for 4 hours
and 30 minutes to either normal air (control) or three cycles of 1-hour
7% O2 breathing interrupted by 30 minutes of normal air breathing
(cycling hypoxia), according to [14]. Tumors were collected 16 hours
later (Figure 7). RNA extraction was performed on whole tumors and
not specifically on endothelial cells. mRNA level studies thus reflected
the overall effect of cycling hypoxia on the tumor. Firstly, we
confirmed that cycling hypoxia, by itself, increased PTGS2 (COX-2
coding gene) expression, used as positive control for cycling hypoxia
(Figure 7A). VEGF mRNA expression was also significantly increased
in murine tumors by cycling hypoxia (Supplementary Figure S3). In
addition, cycling hypoxia increased mRNA levels of IL-6 as well as of
CXCL1 (C-X-C motif ligand 1) (KC) and macrophage inflammatory
protein 2 (MIP-2), which are two functional IL-8 murine homologs.
Figure 6. Cycling hypoxia amplifies THP-1 monocyte adhesion on
HUVEC induced by TNFα. EAhy926 cells were exposed to N, chH,
or cyH with or without TNFα (0.1ng/ml) for 6 hours. Directly after
the incubation, calcein-labeled THP-1 monocytes were added on
HUVEC for 1 hour. Endothelial cells were then rinsed to remove
nonadherent monocytes. Results are expressed as the percentage
of THP-1 monocyte adhesion (n=3, mean ±1 SD). Fluorescence
from 600,000 calcein-labeled THP-1 monocytes was used to
determine 100%. Statistical analysis was performed by two-way
ANOVA and Holm-Sidak test as post hoc test. * chH/cyH versus
corresponding N, $ cyH versus corresponding chH, # TNFα versus
corresponding control. $, P b .05; ** P b .01; ***, ###, P b .001.
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under cycling hypoxia. This could be explained by the very low
proportion of endothelial cells in the tumor mass. Furthermore,
tumor imperfect neovasculature in control/cyH mouse tumors
probably exists and could lead to a basal level of inflammation
already up linked to the occurrence of cycling hypoxia events. Thus, it
could be very tricky to demonstrate an increase in adhesion molecule
expression. This remark emphasizes the limitation of our cycling
hypoxia study model where we artificially amplified a phenomenon
naturally occurring in tumors. We also assayed VCAM-1 and SELEFigure 7. Cycling hypoxia enhances proinflammatory gene expression
(A–B) LLc tumor-bearing C57BL/6 mice were exposed to normal a
breathing] followed by 30-minute reoxygenation (21% O2]), or were i
killed. Tumors were collected 16 hours later. (A) The relative abundan
evaluated by RT-qPCR (n=3, mean ±1 SEM). t test was performed as
tumors were immunostained for CD11b (green) and were counterstamRNA expression to try to discriminate the endothelial impact of
cycling hypoxia on tumor inflammation (Supplementary Figure S3).
Both their mRNA expression tended to be increased in cycling hypoxic
tumors, but results were not significant. Therefore, we performed a
functional test to appreciate cycling hypoxia effects on endothelial cells
by immunostaining CD11b (Figure 7B). CD11b is expressed by all
myeloid lineage cells and is required for firm adhesion of leukocytes to
the endothelium by binding to ICAM-1. The abundance of CD11b
was higher in cryosections from cycling hypoxic tumors than from
normoxic tumors, suggesting an increase in leukocyte infiltration into
tumors of mice exposed to cycling hypoxia. Tumors of mice injected
with LPS were used as positive control for specific CD11b
immunostaining. All together, these findings suggest that cycling
hypoxia leads to an amplification of tumor-related inflammation.
Cycling Hypoxia-Induced Amplified Inflammatory Phenotype
and Poor Prognosis in Human Colon Cancer
Finally, we sought to determine whether the inflammatory gene
expression profile amplified by cycling hypoxia could be of clinical
interest for cancer prognosis. We focused on colon cancer for three
reasons: studies have already related the importance in cancer
progression of the genes encoding COX-2 (PTGS2), IL-6, and IL-8
taken separately [31–33]; abnormal morphology of tumor blood
network has been shown in human colon carcinoma [34]; and the
presence of cycling hypoxic areas was evidenced in human colorectal
adenocarcinomas [35]. Firstly, gene expression was quantified in
colon tumor tissue. Results showed that PTGS2, IL-6, and IL-8
mRNA expression was significantly upregulated in tumors versus
corresponding healthy tissues (Figure 8A). Carbonic anhydrase 9
(a specific marker of hypoxia) gene expression was significantly
increased in tumors, indicating that these tumors contained hypoxic
areas (Supplementary Figure S4A). ICAM-1 mRNA level was
increased in six patients out of seven, but this was not statistically
significant. SELE mRNA expression was increased in seven patients
out of seven, whereas VCAM-1 mRNA expression was notand leads to an increase in leukocyte infiltration in tumors in mice.
ir (control) or cyH (4h30) (three cycles of 1-hour hypoxia [7% O2
njected with LPS (1 mg/kg) 44 hours and 30 minutes before being
ce of PTGS2, IL-6, KC, MIP-2, and ICAM-1 mRNA into tumors was
statistical analysis. *, P b .05 cyH versus Control. (b) Cryosections of
ined with DAPI (blue).
Figure 8. Cycling hypoxia-specific proinflammatory phenotype is associated with poor prognosis in human colon cancer. (A) Healthy and
tumor biopsies from seven patients with colon cancer were collected and were used to evaluate PTGS2, IL-6, IL-8, and ICAM-1 mRNA
expression by RT-qPCR. ΔCt of tumor is compared to ΔCt of healthy tissue for each patient. Statistical analysis was performed by Wilcoxon
test. (B–C) Public Affymetrix array data of 176 colon cancer patients (GSE17536) for whom cancer-specific survival time is known were
reanalyzed. Patients were stratified into two subgroups for each presented graph according to themedian value, and Kaplan-Meier plots were
drawn. The first graph (B) represents the probability of DSS for patients who display ICAM-1high/IL-6high/IL-8high expression phenotype (red)
versus patientswith other phenotypes (black), the secondgraph (C) patientswith PTGS2high/ICAM-1high/IL-6high/IL-8high expression phenotype
(red) versus patients with other phenotypes (black), and the third graph (D) patients with BIRC5low/PTGS2high/ICAM-1high/IL-6high/IL-8high
expression phenotype (red) versus patients with other phenotypes (black). Gehan-Breslow-Wilcoxon test was used for statistical analysis.
Hazard ratio (ratio of instant risk of death between groups) is also denoted.
Neoplasia Vol. 17, No. 1, 2015 Cycling Hypoxia and Inflammation Tellier et al. 75significantly dysregulated (Supplementary Figure S4A). Secondly, we
analyzed gene expression data of a public Affymetrix dataset
(GSE17536) involving 176 patients with colon cancer [17]. To
know if the cycling hypoxia–amplified inflammatory phenotype
identified in this work could be used as a prognosis biomarker,
survival analyses using the Kaplan-Meier method were performed.
Patients were primarily stratified into two equal subgroups, based on
the median value, according to the expression of one gene (i.e.,
PTGS2, IL-6, IL-8, ICAM-1), and the probability of DSS for patients
with lower or higher gene expression was compared (Supplementary
Figure S4B). None of the genes, by their own expression,demonstrated a significant influence on the probability of survival,
even for PTGS2 already well known to have an increased expression
in colon cancer (Supplementary Figure S4B). Patients were then
subdivided as a function of the expression of several genes taken
simultaneously. We paralleled the probability of specific cancer
survival between patients displaying a simultaneous high expression of
ICAM-1, IL-6, and IL-8 and patients with all the other expression
phenotypes (Figure 8B). Patients with ICAM-1high/IL-6high/IL-8high
phenotype had a significantly lower survival probability than others
(P b .05). This was not the case if we only considered the expression
of IL-6 and IL-8 taken together (data not shown). Finally, we
76 Cycling Hypoxia and Inflammation Tellier et al. Neoplasia Vol. 17, No. 1, 2015integrated all the criteria evidenced in the previous results, a
simultaneous PTGS2high, ICAM-1high, IL-6high, and IL-8high
expression, to subdivide patients into two groups (Figure 8C).
Patients with this inflammatory expression phenotype had a
significant probability of colon cancer specific survival, with 2.4-
fold more risk of cancer death. Thus, results demonstrated that
inflammation amplified by cycling hypoxia is protumoral. Afterwards,
we wanted to highlight an inflammatory expression phenotype
specifically associated to cycling hypoxia and not just an inflammatory
phenotype. For that, we added a cycling hypoxia–specific expression
marker described by Boidot et al., [36] to the inflammatory signature.
Indeed, these authors generated a very robust transcriptomic cycling
hypoxia signature from Affymetrix analyses on mRNA extracts of 20
tumor cell lines exposed during 24 hours under cycling hypoxia
(30-minute normoxia [21% O2] followed by 30-minute hypoxia [1%
O2]) or 24 hours under normoxia. Thanks to these analyses, they
identified the 100 first most differentially expressed genes in cells
exposed to cycling hypoxia in comparison to cells maintained under
normoxia. For our analysis, we just took in consideration the first top
gene that is the most differentially expressed, BIRC5, characterized by
a lower expression under cycling hypoxia. Firstly, we stratified
patients into two equal groups according to the expression of BIRC5
alone (Supplementary Figure S4C). Results showed that patients with
a lower expression of BIRC5 had a significant lower probability of
survival. So, BIRC5, by its own expression, is able to significantly
separate survival curves for patients with colon cancer. Finally, we
compared survival curves between patients expressing the inflamma-
tory phenotype specifically associated to cycling hypoxia, defined by a
simultaneous expression of BIRC5low, PTGS2high, ICAM-1high, IL-
6high, and IL-8high, and patients with another phenotype. This
specific signature is able to discriminate patients with a very low
probability of cancer survival (5.5-fold more risk of death). This new
and original phenotype could thus be used as a biomarker of poor
prognosis in colon cancer.
Discussion
As suggested by Rofstad et al., [37], cycling hypoxia may constitute a
more serious problem for cancer patient treatment than chronic
hypoxia. Indeed, the fraction of cycling hypoxic cells is generally
larger than the one of chronic hypoxic cells. Moreover, cycling
hypoxic tumor cells have a higher metastatic potential than chronic
tumor cells. This could be related to their close localization to blood
vessels, as well as to their higher energetic status [37]. Furthermore,
cycling hypoxia, in contrast to chronic hypoxia, also promotes
endothelial cell survival and increases their capacity to migrate and to
form tubes, hence favoring tumor angiogenesis [14,16]. But, until
now, nobody studied the possible relationship between cycling
hypoxia and tumor inflammation.
Endothelial cells, key regulators of tumor growth, differentially
respond to changes in tumor microenvironment [38], as exemplified
during inflammation when TNFα targets endothelial cells, leading to
the upregulation of some cell surface receptors and facilitating
leukocyte transmigration [39]. We therefore hypothesized that
endothelial cells could be a perceptive sensor of cycling hypoxia and
inflammation simultaneously. Results showed that endothelial cells
exposed to cycling hypoxia displayed an amplified inflammatory
phenotype, characterized by an increase in TNFα-induced IL-8,
ICAM-1, PTGS2, SELE, and VCAM-1 mRNA levels and TNFα-
induced IL-6 and IL-8 secretion. Furthermore, cycling hypoxiasustained ICAM-1 protein expression enhanced by TNFα. Effects of
cycling hypoxia were already clear after 6 hours, which is a relatively
short duration, but we could probably expect an inflammatory
amplification loop if this phenomenon happens on a longer time scale
as it is pathophysiologically the case in vivo. Besides, analyses were
performed on a relatively low number of inflammatory genes. It is
highly probable that other inflammatory markers have a TNFα-
induced expression increased by cycling hypoxia.
In parallel, cycling hypoxia efficiently increased NF-κB transcrip-
tional activity. Indeed, cycling hypoxia prolonged the phosphoryla-
tion and degradation of IκBα induced by TNFα and slowed down its
resynthesis in the following cycles of incubation. Cycling hypoxia
could thus delay the negative feedback loop ending the NF-κB
response. The involvement of NF-κB overactivation in the increase in
IL-6, IL-8, and ICAM-1 expression in endothelial cells exposed to
cycling hypoxia was demonstrated using siRNA. Interestingly, NF-κB
is considered as a key molecular link between inflammation and
cancer, and has been shown to be dysregulated in many cancers
[40,41]. Here, we showed in vitro that overactivation of NF-κB could
also participate to the amplification of inflammation through the
induction of endothelial cell proinflammatory phenotype. The
inflammatory phenotype of endothelial cells induced by cycling
hypoxia was biologically confirmed by an increase in THP-1
monocyte adhesion.
The role of cycling hypoxia in cancer-related inflammation in vivo
in tumor-bearing mice was validated, as an increase in IL-6, KC, and
MIP-2 gene expression was also observed. This amplification of
inflammation is probably not only mediated by endothelial cells but
by several other cell types of tumor microenvironment. Nonetheless,
results suggested that a part of the exacerbation of tumor
inflammation by cycling hypoxia could proceed through its effect
on tumor endothelium, as we observed an increase in leukocyte
infiltration. An increased influx of leukocytes into tumors is known to
be an amplificatory mechanism of tumor inflammation with the
continuous secretion of inflammatory mediators [42]. Our in vivo
model confirmed the effects of cycling hypoxia not especially on the
endothelial inflammatory phenotype but on the overall
tumor inflammation.
To determine if the specific subset of genes induced by cycling
hypoxia could be pathophysiologically relevant in human cancer, we
examined whether these genes are upregulated in colon tumor tissue.
IL-6, IL-8, and PTGS2 expression was significantly increased. We
finally demonstrated that cycling hypoxia–specific inflammatory
phenotype, characterized by a simultaneous BIRC5low, PTGS2high,
ICAM-1high, IL-6high, and IL-8high expression, is associated with a
low probability of colon cancer specific survival. We thus highlighted
a new phenotypic biomarker that could be used in clinic to identify
more precisely colon tumors associated with a poor prognosis. As this
inflammatory phenotype may influence cancer growth and metastasis,
it could suggest that cycling hypoxia–amplified inflammation is
protumoral. A good demonstration that the inflammation may
support tumor development came from the data showing that long-
term users of nonsteroidal anti-inflammatory drugs presented a
diminished cancer risk, up to 40% to 50% for colon cancer [43]. Our
results are in line with previous reports, as most of the genes outlined
in this work are already known targets for cancer treatment. Indeed, as
PTGS2 (COX-2 encoding gene) expression is well described to be
increased in colon cancer, COX-2 specific inhibitors, like celecoxib,
were tested in trials as a prevention or therapeutic option in this
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adenomas, they might encounter cause cardiovascular and gastroin-
testinal side effects, preventing their routine use in cancer
management [44]. Likewise, several clinical studies using anti–IL-6
antibodies for cancer treatment have been reported, but they are still
in clinical trials [45]. The novelty of our results is that cycling hypoxia
simultaneously increases the expression of a subset of inflammatory
genes, which accounts for tumor aggressiveness. Because of drug side
effects, it could be more efficient to target this mechanism rather than
each candidate gene independently. Hence, a new approach to reduce
tumor-promoting inflammation could be to specifically prevent
cycling hypoxia occurrence, as for instance by “vasculature
normalization treatment” [46]. All together, our findings suggest
that preventing cycling hypoxia to occur could be an ingenious way
by which colon cancer treatment would be improved.
In conclusion, our results evidenced a new mechanism that
accounts for the amplification of tumor-related inflammation,
initiated by cycling hypoxia, which favors tumor aggressiveness.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.11.003.
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